Altimmune said that it has signed an agreement with DynPort Vaccine Company regarding Altimmune’s AdCovid intranasal vaccine candidate for COVID-19. The company announced in March 2020 that it had partnered with the University of Alabama Birmingham to develop AdCOVID.
According to Altimmune, “The partnership with DVC significantly expands Altimmune’s capabilities to efficiently obtain and execute on US Government funding opportunities to support the development of AdCOVID” given DynPort’s experience with funding from the Department of Defense, the Biomedical Advance Research and Development Authority (BARDA), and the National Institute of Allergy and Infectious Diseases (NIAID). DynPort may also eventually provide other services, including program management and regulatory support.
Two of Altimmune’s intranasal candidates are already funded by the US government. BARDA is providing up to $133.7 million in funding for development of the company’s NasoShield intranasal anthrax vaccine, and the US Army Medical Research & Development Command is providing $4.7 million for its T-COVID intranasal therapy for early-stage COVID-19. Altimmune recently announced the initiation of a Phase 1/2 trial of T-COVID.
The company also said that it expects to have the results of preclinical studies of AdCOVID “in the near term” and that manufacturing should begin during the third quarter, with a Phase I trial expected to begin in the fourth quarter.
Read the Altimmune press release.
